AC-200

AC-200, or Phosphatonin, is a human endogenous protein that regulates phosphate (PO₄) metabolism. Acologix is investigating AC-200 in preclinical studies for the treatment of hyperphosphatemia, an elevated level of phosphate in the blood, which commonly occurs in patients with advanced renal failure. Patients with hyperphosphatemia have an increased risk of bone disease and cardiovascular events including heart attach and stroke. In preclinical studies with healthy and chronic kidney disease models, AC-200 has shown inhibition of phosphate absorption in the intestine, inhibition of phosphate re-absorption in the kidney, and reduction of serum phosphate levels.

In June 2006, Acologix entered into a development and license agreement with Toray for AC-200. Under this agreement, Acologix has granted Toray an exclusive license to AC-200 in Japan.